Physician profile
Magdala Poon
NPI 1144541202
$17,223.81
in general payments reported to CMS, 2019-2025
80 companies · $3,254 in 2025
The $3,254 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,237 · 2020: $1,658 · 2021: $2,296 · 2022: $2,650 · 2023: $2,674 · 2024: $3,454 · 2025: $3,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,381.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,034.75 | 2019-2025 | |
| Ucb, INC. | $1,608.59 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Novartis Pharmaceuticals Corporation | $1,234.33 | 2019-2025 | |
| Biogen, INC. | $1,144.10 | 2019-2025 | Vumerity, Leqembi, Skyclarys |
| Acadia Pharmaceuticals INC | $834.06 | 2019-2025 | Nuplazid, Daybue |
| Neurocrine Biosciences, INC. | $688.79 | 2020-2025 | Ingrezza, Ongentys |
| Eisai INC. | $508.70 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $489.67 | 2019-2023 | Austedo |
| Amgen INC. | $470.98 | 2019-2025 | Uplizna |
| Genentech USA, INC. | $434.92 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Lundbeck LLC | $426.83 | 2020-2025 | Vyepti |
| Sk Life Science, INC. | $387.53 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $376.56 | 2019-2025 | Ultomiris, Soliris |
| Allergan, INC. | $301.56 | 2020-2022 | |
| Lilly USA, LLC | $286.62 | 2019-2025 | Amyvid, Kisunla, Reyvow |
Show all 80 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magdala Poon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.